Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 an...() and high-grade cervical dysplasia (CIN...)

Date:10/8/2008

) and high-grade cervical dysplasia (CIN 2/3). The planned Phase 2 trials consist of multi-center, randomized, double-blind, placebo-controlled studies in the U.S., Canada, Europe and Latin America. For the CIN 2/3 study, protocol development, discussions with the U.S. Food and Drug Administration and site evaluations have been completed. A second protocol for the CIN 1 indication is near completion. Partnering or adequate financing are required for the trials to be initiated.

Poly-ICR -- Proprietary Toll-like Receptor 3 Agonist

The company's proprietary Toll-like Receptor 3 agonist, Poly-IC: Poly-Arginine (Poly-ICR), may have use as a broad immune stimulatory agent, as well as a vaccine adjuvant for both therapeutic and prophylactic vaccines. Nventa is currently advancing Poly-ICR as a means for revenue generation through partnering, as well as for its own internal development.

-- Partnering Poly-ICR -- Nventa is currently providing Poly-ICR through Material Transfer Agreements to leading vaccine developers in the U.S. and abroad who are evaluating Poly-ICR for potential incorporation into a wide range of vaccine products. Based on early interest in Poly-ICR, the company anticipates that it may provide Nventa with a near-term revenue opportunity.

-- Internal Application of Poly-ICR -- Nventa is pursuing the development of Poly-ICR for topical application for the treatment of genital warts (GW) and actinic keratosis, a premalignant condition of the skin. Next development activities include completing toxicology and formulation activities for Poly-ICR and filing an investigational new drug (IND) application for the compound. Partnering or adequate financing are required for this work to be continued.

Hsp 6/11 -- Preclinical Product Candidate for the Treatment of GW and RRP

The company has nominated Hsp 6/11 as a development candidate targeting the treatment of GW and recurrent respiratory papillomatosis (RRP), a disease in wh
'/>"/>

SOURCE Nventa Corporation Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update